A Phase 2 interventional study of Ginger and Placebo in Chemotherapy-induced Nausea and Vomiting, sponsored by Mahidol University. Completed at 1 site in Thailand. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-03-16.
Sponsored by Mahidol University · Phase 2, Interventional, and Supportive care
Breast cancer patient receiving AC regimen chemotherapy (Doxorubicin + Cyclophosphamide) who has nausea score from 40/100 VAS or vomiting after the first or second cycle of chemotherapy is recruited. The patient who meets the eligibility criteria and provides informed consent is randomised to receive either Ginger capsule (500 mg) or placebo taking twice a day by mouth during the first 5 days of chemotherapy cycle. The study drug will be switched on the subsequent cycle (i.e. the patient who received Ginger capsule will receive placebo and vice versa). The primary outcome is the nausea score and vomiting during the first 5 days of each chemotherapy cycle when receiving the study drug.
822 studies on the registry are indexed under Nausea; 104 are open to participants now.
This study's enrollment of 34 is below the median of 115 across 703 interventional studies indexed under Nausea.
Browse Nausea studies →Mahidol University is the lead sponsor of 730 studies on the registry; 118 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Ginger capsule (500 mg) taking twice a day by mouth during the first 5 days of chemotherapy cycle
Drug: Ginger
Placebo capsule taking twice a day by mouth during the first 5 days of chemotherapy cycle
Drug: Placebo
Ginger capsule (500 mg) taking twice a day by mouth during the first 5 days of chemotherapy cycle
Placebo capsule taking twice a day by mouth during the first 5 days of chemotherapy cycle
Nausea score
Time frame: The first 5 days of chemotherapy cycle
This study is completed, as verified in Mar 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Mahidol University